Reappraising cardiac function with myocardial contraction fraction: normal values, disease detection, and prognostication

European Heart Journal - Cardiovascular Imaging

22 January 2026
Organised by: Logo
ESC Journals HEART FAILURE Chronic Heart Failure HYPERTENSION IMAGING Cardiac Magnetic Resonance (CMR) VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE Myocardial Disease

Abstract

AbstractAims

Assessing cardiac function is critical for managing cardiovascular disease, guiding treatment, monitoring progression, and risk stratification. While left ventricular (LV) ejection fraction (LVEF) is firmly established, it has limitations. Myocardial contraction fraction (MCF)—the ratio of stroke volume to myocardial volume, is simple to compute without additional analysis and offers a promising alternative to LVEF.

Methods and results

MCF was assessed across four datasets spanning healthy controls and chronic structural cardiac disease, with direct comparison to LVEF. Association between age, sex, and MCF were investigated in 3541 healthy subjects from the UK Biobank and sex-specific reference ranges derived. Several cohorts were recruited to investigate the discriminative power of MCF and LVEF between health and physiological adaption (n = 278 veteran athletes), pathological hypertrophy [hypertrophic cardiomyopathy, amyloid, Fabry, severe aortic stenosis (AS), and hypertension (HTN); n = 633], and dilatation [n = 103 dilated cardiomyopathy (DCM)]. Ability to track disease severity was assessed by looking at 41 558 subjects from the UK Biobank. Finally, prognostication was assessed on 1277 consecutive patients from an independent external dataset. All images were analysed using the same validated artificial intelligence algorithm. MCF varied with sex (mean MCF: 0.94 male; 1.1 female) but not age. Sex-specific reference ranges were established: [0.68–1.20] for male and [0.82–1.38] for female. MCF decreased in pathological disease (e.g. mean MCF: 0.72 HCM; 0.69 severe AS; 0.5 amyloid; 0.9 HTN) but there was no significant decrease in LVEF other than in amyloid (mean EF: 76% HCM; 64% severe AS; amyloid 56%; 65% HTN). Both MCF and ejection fraction (EF) decreased in DCM (EF 34%; MCF 0.58). MCF decreased with worsening HTN, whereas LVEF increased (P < 0.05). MCF had superior prognostic ability to LVEF (MCF vs. LVEF: HR = 0.772 vs. HR = 0.816; χ2 = 198 vs. χ2 = 151; P < 0.001).

Conclusion

We established MCF reference ranges, showing superior performance for detecting early disease and tracking progression compared with LVEF. MCF offers enhanced prognostic utility, complementing established metrics of LV function.

Contributors

Silvia Castelletti
Silvia Castelletti

Author

Hospital Santa Maria della Misericordia Udine , Italy

Viviana Maestrini
Viviana Maestrini

Author

Sapienza University of Rome Rome , Italy

Lamia Al Saikhan
Lamia Al Saikhan

Author

Imam Abdulrahman Bin Faisal University Dammam , Saudi Arabia

Uzma Gul
Uzma Gul

Author

Thomas A Treibel
Thomas A Treibel

Author

Barts Health NHS Trust London , United Kingdom of Great Britain & Northern Ireland

James C Moon
James C Moon

Author

Barts Heart Centre London , United Kingdom of Great Britain & Northern Ireland